



ASX release

21 May 2018

*AtCor Medical (ASX: ACG, AtCor, the Company) announced earlier today the commencement of a Preliminary Trial in collaboration with Blumio Inc. and Macquarie University. The title to that announcement was potentially misleading in representing Blumio as being responsible for the trial when it is in fact an AtCor trial. The title is corrected in this announcement and the balance of the announcement is as per the same release earlier this day.*

## **AtCor Announces Wearable Cardio Monitor Trial in Strategic Collaboration with Blumio and Macquarie University Health Science**

**AtCor Medical** (ASX: ACG, AtCor, the Company), a leading medical device company providing cardio health management products globally, is pleased to announce that it will commence a Preliminary Trial of the Company's Pulse Wave Analysis (PWA) technology in a strategic collaboration with California Silicon Valley-based wearable blood pressure (BP) sensor company **Blumio Inc.** (Blumio), to be undertaken at the Faculty of Medicine and Health Sciences at Macquarie University, Sydney.

As part of the planned 15 patient, 8-week trial, AtCor will independently assess the feasibility of obtaining cardiovascular BP-related data utilising the Blumio wearable sensor and analysing it via AtCor's PWA technology. As part of a multi-phase program, the first phase of the assessment is to collect sensor data from at least 15 human subjects covering different age groups, different genders and a range of BP characteristics.

The preliminary trial, which includes the assessment of the sensor's response to varying patient manoeuvres and comparison with AtCor's FDA cleared SphygmoCor® PWA parameters, will assist in determining the amount of cardiovascular-related information available from the sensor. This trial will be conducted in collaboration with a team headed by Professor Alberto Avolio in the Faculty of Medicine and Health Sciences at Macquarie University.

Pending success of the first phase trial results, subsequent trials will progress to integrate AtCor's PWA technologies into an existing Blumio wearable sensor product. The first phase is expected to take approximately 8 weeks to complete, including the trial, technical report and stakeholder analysis.

Cardiovascular related mortality accounts for over 30% of global deaths annually and home monitoring using modern wearables and mobile products is a growth industry expected to exceed US\$1.6Bn by 2023 (IEE).

Blumio and AtCor intend to be at the forefront of this developing area of telehealth and can leverage off their strong established client base such as Novartis, GSK, Mayo Clinic and others and our product range such as SphygmoCor® the only non-invasive PWA cardiovascular monitoring device FDA cleared as substantially equivalent in all measures to an invasive catheter.

For personal use only



Professor Alberto Avolio, Faculty of Medicine and Health Sciences at Macquarie University commented:

*“Cardiovascular disease is one of the world’s major health issues and non-invasive tele-monitoring is the cutting edge of the future of Health Science. AtCor and Macquarie University have an established history of collaboration and we are very excited to be working on this trial with pulse wave technology and its use in Blumio’s high sensitivity medtech wearables that could, in the future, significantly enhance positive patient outcomes.”*

AtCor CEO Craig Cooper supported Professor Avolio’s comments:

*“Collaborating with our first-class partners in this trial, Macquarie University and Blumio, ensures that AtCor has every opportunity to succeed in progressing its leading cardiovascular monitoring technology and encompasses our strategy to become a world leader in hypertension and cardiovascular health.”*

### **About Blumio**

Blumio Inc., is a Silicon Valley based California Company that develops non-invasive radio frequency sensors designed to measure blood pressure and other cardiovascular diagnostics. AtCor recently announced an investment of up to US\$600,000 in Blumio to acquire up to 7.5% in the company (ASX 14 March 2018).

### **About AtCor**

AtCor Medical with operations in Sydney, Australia and Chicago, Illinois develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of intervention, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,400 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations.

*For further information, please contact  
(AtCor):*

Chief Executive Officer  
Craig Cooper  
Phone: +61 429 993 399

[c.cooper@atcormedical.com](mailto:c.cooper@atcormedical.com)

*Media enquiries to:*

Investor Relations  
Peter Taylor  
Phone: +61 412 036 231

[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)

For personal use only